SCTX Scribe Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1853921 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets33.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $1.64M | $1.92M | — | $20.11M | $4.90M | — |
| R&D expense | $8.26M | $8.82M | — | $14.42M | $13.88M | — |
| SG&A expense | $4.24M | $2.49M | — | $3.53M | $2.64M | — |
| Operating income | -$10.86M | -$9.39M | — | $2.16M | -$11.63M | — |
| Interest expense | $0 | $276,000 | — | $598,000 | $598,000 | — |
| Pretax income | -$9.63M | -$6.26M | — | $1.80M | -$10.62M | — |
| Income tax | $231,000 | $212,000 | — | $324,000 | -$712,000 | — |
| Net income | -$9.86M | -$6.48M | -$17.35M | $1.47M | -$9.90M | -$3.42M |
| EBITDA | -$10.26M | -$8.79M | — | $2.86M | -$10.93M | — |
| EPS (basic) | -0.68 | -2.62 | — | 0.00 | -4.08 | — |
| EPS (diluted) | -0.68 | -2.62 | — | 0.00 | -4.08 | — |
| Weighted avg. shares (diluted) | 14.50M | 2.48M | — | 2.43M | 2.43M | — |
| Balance sheet | ||||||
| Cash & equivalents | $172.05M | $35.59M | — | $9.88M | $16.66M | — |
| Short-term investments | $2.18M | $7.42M | — | — | — | — |
| Current assets | $178.89M | $45.10M | — | — | — | — |
| PP&E, net | $5.15M | $5.75M | — | — | — | — |
| Total assets | $187.93M | $57.93M | — | — | — | — |
| Current liabilities | $37.93M | $78.70M | — | — | — | — |
| Total liabilities | $62.76M | $102.42M | — | — | — | — |
| Shareholders' equity | $125.17M | -$164.85M | -$158.74M | -$134.16M | -$137.88M | -$128.67M |
| Shares outstanding | 18.94M | 2.49M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$11.25M | — | — | -$11.29M | — | — |
| Capital expenditure | $13,000 | — | — | $325,000 | — | — |
| Free cash flow | -$11.26M | — | — | -$11.62M | — | — |
| Investing cash flow | $5.18M | — | — | $4.52M | — | — |
| Financing cash flow | $142.53M | — | — | $0 | — | — |
| Depreciation & amortization | $600,000 | $600,000 | — | $700,000 | $700,000 | — |
| Stock-based compensation | $1.22M | $227,000 | — | $2.23M | $676,000 | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.